CAR-T cell freezing solution and application thereof
By using frozen solutions of white and polysaccharides, sodium alginate, L-carnitine, tragacanth and human albumin solutions, combined with compound electrolyte injection and procedure cooling technology, the toxicity problem of DMSO was solved and CAR-T was achieved The safe frozen and efficient resuscitation of cells maintains the biological activity and killing ability of cells.
Patent Information
- Application Number
- CN202410957647.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
Smart Images

Figure CN118901701A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cell cryopreservation, and in particular to a CAR-T cell cryopreservation solution without toxic side effects and applications thereof. Background Art
[0002] Immune cell therapy is a new type of therapy that has emerged after surgery, chemotherapy, radiotherapy and targeted therapy, and is known as the "fifth therapy" for cancer treatment.
[0003] CAR-T immune cell therapy (Chimeric Antigen Receptor T-Cell Immunotherapy) uses genetic engineering technology to specifically transform the patient's own immune T cells so that they can recognize tumor cells and achieve specific killing effects.
[0004] The extraction-preparation-amplification method takes a long time to obtain CAR-T cells. After obtaining CAR-T cells, it is easy for changes in treatment factors to make it impossible to use freshly prepared CAR-T cells in time. Therefore, CAR-T cells are usually frozen. How to achieve long-term and effective preservation of CAR-T cells while maintaining the biological activity of CAR-T cells is a problem worthy of attention.
[0005] As an effective method for preserving cells, cell cryopreservation technology has been widely used in the field of biology. Under normal circumstances, directly freezing cells will produce ice crystals that damage the cells, leading to cell death. Therefore, it is necessary to prepare cell freezing solution by adding cryoprotectants to protect the cells.
[0006] At present, the most common cryoprotectant is dimethyl sulfoxide (DMSO), which is a highly osmotic solvent that can quickly penetrate cells, increase the permeability of cell membranes to water, and allow water to pass through cells to form ice crystals before cells freeze, making it the most ideal cryoprotectant for cell freezing. However, low-concentration DMSO is toxic to cells at room temperature and can cause irreversible damage to cell structure and function. Summary of the invention
[0007] In view of the above problems, the problem to be solved by the present invention is to provide a CAR-T cell cryopreservation solution that is safe to use and has no toxic side effects on cells, and a method for cryopreserving cells using the cryopreservation solution.
[0008] The technical solution of the present invention is as follows:
[0009] A CAR-T cell freezing solution comprises 5-15w / v% of Bletilla striata polysaccharide, 3-10w / v% of sodium alginate, 6-14w / v% of L-carnitine, 3-8w / v% of tragacanth gum, 10-30v / v% of human albumin solution, and the rest is a compound electrolyte injection solution.
[0010] Preferably, in one embodiment, the CAR-T cell freezing solution includes 10w / v% of Bletilla striata polysaccharide, 6w / v% of sodium alginate, 9w / v% of L-carnitine, 5w / v% of tragacanth gum, 20v / v% of human albumin solution, and the rest is compound electrolyte injection solution.
[0011] In another embodiment, in the CAR-T cell freezing solution, each 1000 ml of the compound electrolyte injection includes 2-10 g of sodium chloride, 2-10 g of sodium gluconate, 1-6 g of sodium acetate, 0.1-0.8 g of potassium chloride and 0.1-0.7 g of magnesium chloride, and the remainder is water for injection; preferably, each 1000 ml of the compound electrolyte injection includes 5.26 g of sodium chloride, 5.02 g of sodium gluconate, 3.68 g of sodium acetate, 0.37 g of potassium chloride and 0.30 g of magnesium chloride, and the remainder is water for injection.
[0012] When the freezing solution is used, the pH value of the compound electrolyte injection solution needs to be maintained at 7.0-7.8. Therefore, a certain amount of alkaline substances, such as potassium hydroxide, sodium hydroxide, boron hydroxide, etc., need to be added to the electrolyte injection solution.
[0013] The present invention also provides a CAR-T cell cryopreservation method, characterized in that it comprises the following steps:
[0014] The cell solution obtained by mixing the above-mentioned cryopreservation solution with CAR-T cells was placed in a cryopreservation tube and incubated at 4°C for 1 hour;
[0015] Place the cryotube in a programmed cooling box, place it directly in a -80°C environment, and cool it to -80°C at a cooling rate of 1°C / min;
[0016] After cooling, place it directly in a liquid nitrogen tank for storage.
[0017] In the above CAR-T cell cryopreservation method, when the cryopreservation solution is mixed with CAR-T cells, the CAR-T cell density should be controlled to 1.0×10 6 -2.0×10 7 / ml, or 5.0×10 6 -1.0×10 7 cells / ml; for example, the CAR-T cell density can be 1.0×10 6 / ml, 2.0×10 6 / ml, 3.0×106 / ml, 4.0×10 6 / ml, 5.0×10 6 / ml, 6.0×10 6 / ml, 7.0×10 6 / ml, 8.0×10 6 / ml, 9.0×10 6 / ml, 1.0×10 7 / ml, 2.0×10 7 Pieces / ml, etc.
[0018] The CAR-T cell cryopreservation solution provided by the present invention, whose component tragacanth gum can suspend and disperse the cells, improve the viscosity of the cryopreservation solution, slow down the sedimentation rate of the cells, and adsorb on the cell surface to form a barrier to prevent the cells from aggregating and clumping, thereby avoiding the formation of ice crystals outside the cells and damaging the cells. At the same time, it can also enable Bletilla striata polysaccharide and L-carnitine to fully exert the effect of protecting cells, thereby excellently maintaining the cell recovery rate, viability, expansion ability and tumor killing ability after recovery. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is the cell number growth curve of CAR-T cells after thawing for 3 months and then culturing for 13 days;
[0020] Figure 2 This is a bar graph of cell viability and recovery rate after CAR-T cells were frozen for 3 months and then revived and cultured for 13 days;
[0021] Figure 3 This is a bar graph showing the cell killing rate of CAR-T cells after 13 days of culture following thawing after 3 months of cryopreservation. DETAILED DESCRIPTION
[0022] The preferred embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings.
[0023] 1. Preparation of cryopreservation solution and cell cryopreservation
[0024] In the present invention, the preparation of CAR-T cells refers to "Preclinical Study of CD19-CART in the Treatment of B-Cell Hematological Malignancies" by Li Peng et al., and the quality management of CAR-T cells refers to CMBA / T 004.1-2018 "Quality Management Standards for the Preparation of Chimeric Antigen Receptor Modified T Cells (CAR-T Cells)".
[0025] Example 1
[0026] 1.1. Preparation of cryopreservation solution
[0027] Preparation of 100 ml compound electrolyte injection: first, add 0.526 g sodium chloride, 0.502 g sodium gluconate, 0.368 g sodium acetate, 0.037 g potassium chloride and 0.030 g magnesium chloride into water for injection, and fully dissolve and mix; then, add appropriate amount of potassium hydroxide to adjust the pH value of the compound electrolyte injection to 7.3;
[0028] Prepare 100 ml cryopreservation solution: add 10 g of Bletilla striata polysaccharide, 6 g of sodium alginate, 9 g of L-carnitine, and 5 g of tragacanth gum to 20 ml of human albumin solution, and then make up to 100 ml with compound electrolyte injection solution, fully dissolve and mix to obtain CAR-T cell cryopreservation solution.
[0029] 1.2 Cell cryopreservation
[0030] First, according to the CAR-T cell density of 1.0×10 7 / ml, mix the cryopreservation solution prepared in step 1.1 with CAR-T cells to obtain cell fluid; then divide the cell fluid into multiple 5ml cryopreservation tubes, and place the cryopreservation tubes in an incubator at 4°C for 1 hour;
[0031] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0032] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0033] Example 2
[0034] 2.1. Preparation of cryopreservation solution
[0035] Preparation of 100 ml compound electrolyte injection: first, add 0.2 g sodium chloride, 1 g sodium gluconate, 0.1 g sodium acetate, 0.01 g potassium chloride and 0.08 g magnesium chloride into water for injection, and fully dissolve and mix; then, add appropriate amount of sodium hydroxide to adjust the pH value of the compound electrolyte injection to 7.0;
[0036] Prepare 100 ml of freezing solution: add 15 g of Bletilla striata polysaccharide, 3 g of sodium alginate, 9 g of L-carnitine, and 5 g of tragacanth gum to 20 ml of human albumin solution, and then make up to 100 ml with compound electrolyte injection solution, fully dissolve and mix to obtain CAR-T cell freezing solution.
[0037] 2.2 Cell cryopreservation
[0038] First, according to the CAR-T cell density of 1.0×10 6 / ml, mix the cryopreservation solution prepared in step 2.1 with CAR-T cells to obtain cell fluid; then divide the cell fluid into multiple 5ml cryopreservation tubes, and place the cryopreservation tubes in an incubator at 4°C for 1 hour;
[0039] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0040] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0041] Example 3
[0042] 3.1. Preparation of cryopreservation solution
[0043] Prepare 100 ml of compound electrolyte injection: first, add 0.1 g of sodium chloride, 0.2 g of sodium gluconate, 0.6 g of sodium acetate, 0.08 g of potassium chloride and 0.01 g of magnesium chloride into water for injection, and fully dissolve and mix; then, add appropriate amount of boron hydroxide to adjust the pH value of the compound electrolyte injection to 7.8;
[0044] Prepare 100 ml of freezing solution: add 5 g of Bletilla striata polysaccharide, 10 g of sodium alginate, 9 g of L-carnitine, and 5 g of tragacanth gum to 20 ml of human albumin solution, and then make up to 100 ml with compound electrolyte injection solution, fully dissolve and mix to obtain CAR-T cell freezing solution.
[0045] 3.2 Cell cryopreservation
[0046] First, according to the CAR-T cell density of 2.0×10 7 / ml, mix the cryopreservation solution prepared in step 3.1 with CAR-T cells to obtain cell fluid; then divide the cell fluid into multiple 5ml cryopreservation tubes, and place the cryopreservation tubes in an incubator at 4°C for 1 hour;
[0047] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0048] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0049] Example 4
[0050] 4.1. Preparation of cryopreservation solution
[0051] Prepare 100 ml of compound electrolyte injection: first, add 0.4 g of sodium chloride, 0.65 g of sodium gluconate, 0.6 g of sodium acetate, 0.035 g of potassium chloride and 0.052 g of magnesium chloride into water for injection, and fully dissolve and mix; then, add appropriate amount of potassium hydroxide to adjust the pH value of the compound electrolyte injection to 7.4;
[0052] Prepare 100 ml of freezing solution: add 12.5 g of Bletilla striata polysaccharide, 8.5 g of sodium alginate, 6 g of L-carnitine, and 8 g of tragacanth gum to 30 ml of human albumin solution, and then make up to 100 ml with compound electrolyte injection solution, fully dissolve and mix to obtain CAR-T cell freezing solution.
[0053] 4.2 Cell Cryopreservation
[0054] First, according to the CAR-T cell density of 5.0×10 6 / ml, mix the cryopreservation solution prepared in step 4.1 with CAR-T cells to obtain cell fluid; then divide the cell fluid into multiple 5ml cryopreservation tubes, and place the cryopreservation tubes in an incubator at 4°C for 1 hour;
[0055] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0056] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0057] Example 5
[0058] 5.1. Preparation of cryopreservation solution
[0059] Prepare 100 ml of compound electrolyte injection: first, add 0.635 g of sodium chloride, 0.37 g of sodium gluconate, 0.18 g of sodium acetate, 0.062 g of potassium chloride and 0.031 g of magnesium chloride into water for injection, and fully dissolve and mix; then, add appropriate amount of sodium hydroxide to adjust the pH value of the compound electrolyte injection to 7.6;
[0060] Prepare 100 ml cryopreservation solution: add 5 g of Bletilla striata polysaccharide, 3 g of sodium alginate, 10 g of L-carnitine, and 3 g of tragacanth gum to 30 ml of human albumin solution, and then make up to 100 ml with compound electrolyte injection solution, fully dissolve and mix to obtain CAR-T cell cryopreservation solution.
[0061] 5.2 Cell Cryopreservation
[0062] First, according to the CAR-T cell density of 1.5×10 7 / ml, mix the cryopreservation solution prepared in step 5.1 with CAR-T cells to obtain cell solution; then divide the cell solution into multiple 5ml cryopreservation tubes, and place the cryopreservation tubes in an incubator at 4°C for 1 hour;
[0063] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0064] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0065] Example 6
[0066] 6.1. Preparation of cryopreservation solution
[0067] Prepare 100 ml of compound electrolyte injection: first, add 0.25 g of sodium chloride, 0.43 g of sodium gluconate, 0.51 g of sodium acetate, 0.043 g of potassium chloride and 0.055 g of magnesium chloride into water for injection, and fully dissolve and mix; then, add appropriate amount of sodium hydroxide to adjust the pH value of the compound electrolyte injection to 7.1;
[0068] Prepare 100 ml cryopreservation solution: add 15 g of Bletilla striata polysaccharide, 10 g of sodium alginate, 10 g of L-carnitine, and 5 g of tragacanth gum to 10 ml of human albumin solution, and then make up to 100 ml with compound electrolyte injection solution, fully dissolve and mix to obtain CAR-T cell cryopreservation solution.
[0069] 6.2 Cell Cryopreservation
[0070] First, according to the CAR-T cell density of 8.0×10 6 / ml, mix the cryopreservation solution prepared in step 6.1 with CAR-T cells to obtain cell fluid; then divide the cell fluid into multiple 5ml cryopreservation tubes, and place the cryopreservation tubes in an incubator at 4°C for 1 hour;
[0071] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0072] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0073] Example 7 (Comparative Example 1, the cryopreservation solution does not contain tragacanth gum component)
[0074] First, according to the CAR-T cell density of 1.0×10 7 / ml, a cell freezing solution containing 90v / v% fetal bovine serum and 10v / v% dimethyl sulfoxide is mixed with the CAR-T cells to obtain a cell solution; the cell solution is then dispensed into multiple 5ml cryopreservation tubes, and the cryopreservation tubes are placed in an incubator at 4°C for 1 hour;
[0075] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0076] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0077] Example 8 (Comparative Example 2, the cryopreservation solution does not contain dimethyl sulfoxide, fetal bovine serum and tragacanth gum components)
[0078] First, according to the CAR-T cell density of 1.0×10 7 / ml, the commercially available cell freezing solution from Irvine Scientific was mixed with CAR-T cells to obtain cell solution; the cell solution was then dispensed into multiple 5ml cryopreservation tubes, and the cryopreservation tubes were placed in an incubator at 4°C for 1 hour;
[0079] Next, the cryotube was placed in a programmed cooling box and directly placed in a -80°C environment, and cooled to -80°C at a cooling rate of 1°C / min;
[0080] Finally, after the cooling of the programmed cooling box is completed, all cryopreserved tubes are placed in a liquid nitrogen tank for storage and standby use.
[0081] 2. Functional testing of CAR-T cells after cryopreservation and resuscitation
[0082] Example 9 Growth and expansion detection of CAR-T cells after cryopreservation and thawing
[0083] The cryopreserved tubes in Examples 1 to 8 after being frozen for 3 months were taken respectively, placed in a 37°C constant temperature water bath for rapid recovery, shaken until the cell suspension was completely thawed, centrifuged at 1200r / min, the cryopreserved solution was discarded, and the CAR-T cell suspension was resuspended in 1640 medium containing 10% fetal bovine serum by volume. The recovered CAR-T cells were then cultured according to routine methods for 13 days, and the number of CAR-T cells was counted using a cell counter on day 0, day 3, day 5, day 7, day 9, day 11, and day 13, respectively. The statistical results are shown in Tables 1 and 1; Tables 1 and 2 Figure 1 The data are consistent.
[0084] Table 1 Growth number of CAR-T cells after thawing for 3 months (×10 7 pcs / ml)
[0085] Example Day 0 Day 3 Day 5 Day 7 Day 9 Day 11 Day 13 Example 1 1 2.6 7.8 17.9 43.8 95.6 197.5 Example 2 1 2.1 5.4 13.7 29.8 67.3 178.7 Example 3 1 2.3 4.5 11.8 27.3 72.8 168.4 Example 4 1 2.5 5.3 13.2 29.5 88.5 180.3 Example 5 1 2.3 4.6 11.5 34.5 73.6 164.8 Example 6 1 2.4 5.3 12.9 38.3 84.5 171.3 Example 7 1 1.3 3.1 6.5 13.3 30.2 89.4 Example 8 1 1.2 2.8 6.1 12.4 26.3 79.8
[0086] From Table 1 and Figure 1 It can be seen that after the cells in Examples 1 to 6 were frozen and revived, their growth was significantly better than that of the cells in Examples 8 to 9, which was basically more than 2 times; this is because the component tragacanth gum in the cryopreservation solution can be adsorbed on the cell surface to form a barrier to prevent cell aggregation, avoid the formation of ice crystals outside the cells and damage the cells, and ensure that the revived cells have the same rapid growth activity and proliferation as in the initial state.
[0087] Example 10 Detection of cell viability and recovery rate after cell cryopreservation and thawing
[0088] 10.1CAR-T cell cryopreservation and recovery
[0089] The cryopreserved tubes in Examples 1 to 8 after being frozen for 3 months were taken respectively, placed in a 37°C constant temperature water bath for rapid recovery, shaken until the cell suspension was completely melted, centrifuged at 1200 r / min, the cryopreserved solution was discarded, washed twice with DPBS solution, and resuspended in 1640 culture medium containing 10% fetal bovine serum by volume to prepare a CAR-T cell suspension.
[0090] 10.2 Cell viability and recovery rate detection
[0091] The cell suspension was taken out for AO / PI staining to detect cell viability and recovery rate.
[0092] Cell viability = number of live cells / total number of cells;
[0093] Cell recovery rate = number of live cells after recovery / number of cells before freezing.
[0094] The results of cell viability and recovery rate are shown in Table 2 and Figure 2 As shown in Table 2 and Figure 2 The data are consistent.
[0095] Table 2 Results of cell viability and recovery rate after 3-month cryopreservation
[0096] Example Cell viability (%) Cell recovery rate (%) Example 1 97.45 94.78 Example 2 94.68 92.33 Example 3 95.17 93.41 Example 4 94.57 92.74 Example 5 94.49 93.08 Example 6 93.43 92.75 Example 7 64.43 62.79 Example 8 51.38 49.24
[0097] Table 2 and Figure 2 The data were statistically analyzed and found to be significantly different, p < 0.05. Figure 2It can be seen that the viability and recovery rate of the cells after the cryopreserved cells in Examples 1 to 6 are better than the viability and recovery rate of the cells after the cryopreserved cells in Examples 7 (Comparative Example 1) and 8 (Comparative Example 2). This is because the component tragacanth gum in the cryopreservation solution can suspend and disperse the cells, slow down the sedimentation rate of the cells, and adsorb on the cell surface to form a barrier to prevent the cells from agglomerating and agglomerating, avoiding the formation of ice crystals outside the cells and damaging the cells, while allowing the Bletilla striata polysaccharide and L-carnitine to fully play the role of protecting the cells, thereby greatly improving the cell recovery rate and viability after recovery.
[0098] In addition, the traditional cell cryopreservation solution of Example 7 (Comparative Example 1, the cryopreservation solution contains fetal bovine serum and dimethyl sulfoxide) and the cell cryopreservation solution of Example 8 (Comparative Example 2, the cryopreservation solution does not contain fetal bovine serum and dimethyl sulfoxide), in Example 7, the viability and cell recovery rate of CAR-T cells are significantly improved. Dimethyl sulfoxide and fetal bovine serum, this is because dimethyl sulfoxide can prevent cells from forming ice crystals and avoid cell damage during cell cryopreservation, while fetal bovine serum can provide nutrition to the frozen cells, which also leads to a good improvement in cell viability and cell recovery rate after cell cryopreservation and recovery.
[0099] Example 11 Detection of the ability of CAR-T cells to eliminate tumor cells in vitro
[0100] NALM-6 cells were used as target cells and detected by target cell CFSE dilution assay. The control group was non-frozen CAR-T cells.
[0101] The cryopreserved tubes in Examples 1 to 8 after being frozen for 3 months were taken respectively, placed in a 37°C constant temperature water bath for rapid recovery, shaken until the cell suspension was completely melted, centrifuged at 1200 r / min, the cryopreserved solution was discarded, washed twice with DPBS solution, and resuspended in 1640 culture medium containing 10% fetal bovine serum by volume to prepare a CAR-T cell suspension.
[0102] The target cells NALM-6 and the effector cells CAR-T cells were mixed cultured according to the effector-target ratio E:T=3:1; the results of the in vitro tumor cell elimination ability test of CAR-T cells are shown in Table 3 and Figure 3 As shown in Table 3 and Figure 3 The data are consistent.
[0103] Table 3 CAR-T cell toxicity percentage after 3 months of cryopreservation (effect-target ratio E:T=3:1)
[0104] Example Cell killing rate (%) Example 1 87.82 Example 2 84.27 Example 3 85.57 Example 4 83.33 Example 5 85.02 Example 6 82.54 Example 7 44.45 Example 8 51.27 Control group 92.58
[0105] Table 3 and Figure 3 The data were statistically analyzed and found to be significantly different, p < 0.05. Figure 3It can be seen that the cell killing rate after the cryopreserved cells in Examples 1 to 6 are better than the cell killing rate after the cryopreserved cells in Examples 7 (Comparative Example 1) and 8 (Comparative Example 2). This is because the tragacanth gum provided by the present invention can suspend and disperse cells, slow down the sedimentation rate of cells, and adsorb on the cell surface to form a barrier to prevent cell aggregation, so that the cells are fully protected by the cryoprotectant during the freezing process, so that the cells have a high recovery rate and high viability after recovery, and maintain good activity; therefore, there is still a high cell killing rate after recovery.
[0106] It should be understood that the above description of the preferred embodiments of the present invention is relatively detailed and cannot be regarded as limiting the scope of patent protection of the present invention. The scope of patent protection of the present invention shall be based on the attached claims.
Claims
1. A CAR-T cell freezing solution, characterized in that: It includes 5-15w / v% of Bletilla striata polysaccharide, 3-10w / v% of sodium alginate, 6-14w / v% of L-carnitine, 3-8w / v% of tragacanth gum, 10-30v / v% of human albumin solution, and the rest is compound electrolyte injection.
2. The CAR-T cell cryopreservation solution according to claim 1, characterized in that: It includes 10w / v% of Bletilla striata polysaccharide, 6w / v% of sodium alginate, 9w / v% of L-carnitine, 5w / v% of tragacanth gum, 20v / v% of human albumin solution, and the rest is compound electrolyte injection.
3. The CAR-T cell cryopreservation solution according to claim 1 or 2, characterized in that: Every 1000 ml of the compound electrolyte injection includes 2-10 g of sodium chloride, 2-10 g of sodium gluconate, 1-6 g of sodium acetate, 0.1-0.8 g of potassium chloride and 0.1-0.7 g of magnesium chloride, and the remainder is water for injection.
4. The CAR-T cell cryopreservation solution according to claim 3, characterized in that: Each 1000 ml of the compound electrolyte injection includes 5.26 g of sodium chloride, 5.02 g of sodium gluconate, 3.68 g of sodium acetate, 0.37 g of potassium chloride and 0.30 g of magnesium chloride, and the remainder is water for injection.
5. The CAR-T cell cryopreservation solution according to claim 3, characterized in that: The pH value of the compound electrolyte injection is 7.0-7.
8.
6. The CAR-T cell cryopreservation solution according to claim 5, characterized in that: An alkaline substance is also added to the composite electrolyte injection to maintain its pH value at 7.0-7.
8.
7. The CAR-T cell cryopreservation solution according to claim 6, characterized in that: The alkaline substance includes sodium hydroxide, potassium hydroxide and boron hydroxide.
8. A CAR-T cell cryopreservation method, characterized in that: The steps include: The cell solution obtained by mixing the cryopreservation solution of claim 1 with CAR-T cells is placed in a cryopreservation tube and incubated at 4°C for 1 hour; Place the cryotube in a programmed cooling box, place it directly in a -80°C environment, and cool it to -80°C at a cooling rate of 1°C / min; After cooling, place it directly in a liquid nitrogen tank for storage.
9. The CAR-T cell cryopreservation method according to claim 8, characterized in that: When the cryopreservation solution was mixed with CAR-T cells, the density of CAR-T cells was controlled to be 1.0×10 6 -2.0×10 7 Pieces / ml.
